BTX - BioTime, Inc.

NYSE American - Nasdaq Real-time price. Currency in USD
2.400
+0.030 (+1.27%)
As of 11:36AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close2.370
Open2.370
Bid0.000 x 1200
Ask0.000 x 1000
Day's range2.360 - 2.410
52-week range2.080 - 3.210
Volume127,666
Avg. volume349,853
Market cap304.495M
Beta2.71
PE ratio (TTM)N/A
EPS (TTM)-1.111
Earnings date31 Jul 2018 - 6 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.63
Trade prices are not sourced from all markets
  • June Fundamental Stock Pick: Forbuild SA (WSE:BTX)
    Simply Wall St.6 days ago

    June Fundamental Stock Pick: Forbuild SA (WSE:BTX)

    Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Forbuild SA (WSE:BTX) due to its excellent fundamentals in more thanRead More...

  • Business Wire9 days ago

    AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence

    Following the sale, BioTime owns approximately 80.6% of AgeX’s outstanding shares and Juvenescence and its principals owns approximately 7%. “AgeX is positioned to be a leader in developing therapeutics targeting some of the most compelling opportunities in the commercial market associated with aging,” said Dr. Greg Bailey, M.D. CEO of Juvenescence.

  • Business Wire12 days ago

    BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was submitted to the U.S. Securities and Exchange Commission (the “SEC”). The draft registration statement relates to the proposed distribution of some or all of BioTime’s shares of AgeX Therapeutics, Inc. (“AgeX”) common stock, on a pro rata basis, to BioTime’s shareholders of record as of a date to be determined.

  • Business Wire15 days ago

    AgeX Therapeutics Appoints John F. Mauldin to Board of Directors

    AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. focused on prolonging healthspan through an understanding of the fundamental mechanisms of human aging, today announced the appointment of financial expert, commentator, and bestselling author John F.

  • Business Wire21 days ago

    BioTime to Present at the 8th Annual LD Micro Invitational

    BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at the 8th Annual LD Micro Invitational Conference on Monday, June 4, 2018 at 1:30pm PT, at the Luxe Sunset Bel Air Hotel in Los Angeles, California.

  • Business Wire22 days ago

    BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million. OpRegen® is currently in a Phase I/IIa clinical study, which in March 2018 received authorization from the Data Safety Monitoring Board (DSMB) to move forward with enrollment of cohort 4.

  • Business Wire22 days ago

    BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million. OpRegen® is currently in a Phase I/IIa clinical study, which in March 2018 received authorization from the Data Safety Monitoring Board (DSMB) to move forward with enrollment of cohort 4.

  • Business Wire27 days ago

    BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen®, with the addition of two new U.S. sites that are expected to begin treating patients later this quarter. “The addition of these two leading U.S. clinical trial sites is in addition to our current two sites in California.

  • Business Wirelast month

    AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London

    AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. , today announced that the company’s Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will deliver a keynote presentation at World Advanced Therapies & Regenerative Medicine Congress, May 16-18 in London.

  • Business Wirelast month

    AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London

    ALAMEDA, Calif.--(BUSINESSWIRE)-- AgeX Therapeutics , Inc., a subsidiary of BioTime, Inc . (NYSE American: BTX), today announced that the company’s Chief Executive Officer Michael D. West, Ph.D., who also ...

  • Associated Presslast month

    BioTime: 1Q Earnings Snapshot

    The Alameda, California-based company said it had a loss of 50 cents per share. Losses, adjusted for non-recurring costs, were 9 cents per share. The biotechnology company posted revenue of $701,000 in ...

  • Business Wirelast month

    BioTime Reports First Quarter Results and Recent Corporate Accomplishments

    BioTime, Inc.  , a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ended March 31, 2018 and recent corporate accomplishments.

  • Business Wire2 months ago

    AgeX Announces NIH Grant Award

    AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced the award of a grant of approximately $386,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The grant provides funding for continued development of the company’s technologies for treating stroke. “In this highly-competitive environment, this grant is a validation of our core technology,” commented Michael D. West, Ph.D., CEO of AgeX.

  • Business Wire2 months ago

    BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO

    BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen® for dry-AMD, was presented at the Association for Research in Vision and Ophthalmology  meeting taking place from April 29th – May 3rd, 2018, in Honolulu, Hawaii.

  • Business Wire2 months ago

    BioTime to Announce First Quarter 2018 Results on May 10, 2018

    BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10, 2018, after the close of the U.S.

  • Business Wire2 months ago

    Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018

    BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology  meeting taking place from April 29th – May 3rd, 2018, in Honolulu, Hawaii.

  • BioTime (BTX): Moving Average Crossover Alert
    Zacks2 months ago

    BioTime (BTX): Moving Average Crossover Alert

    BioTime, Inc. (BTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

  • Business Wire2 months ago

    Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit

    BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® trial will be presented at the upcoming Fifth Annual Retinal Cell and Gene Therapy Innovation Summit.

  • Business Wire3 months ago

    BioTime Announces Cash Sale of Ascendance Biotechnology

    BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that IVT Holdings acquired Ascendance Biotechnology, Inc.

  • Associated Press3 months ago

    BioTime reports 4Q loss

    On a per-share basis, the Alameda, California-based company said it had a loss of 58 cents. Losses, adjusted for non-recurring costs, came to 8 cents per share. The biotechnology company posted revenue ...

  • Business Wire3 months ago

    BioTime Reports Fourth Quarter and Fiscal 2017 Results

    BioTime, Inc.  , a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017.

  • BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session
    Zacks3 months ago

    BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session

    BioTime (BTX) was a big mover last session, as the company saw its shares rise 6% on the day amid huge volumes.

  • Business Wire3 months ago

    BioTime Submits CE Mark Application for European Approval of Renevia®

    BioTime, Inc. , a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design dossier application for CE Mark approval to market Renevia® in Europe.

  • Business Wire3 months ago

    BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial

    BioTime, Inc. , a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the independent Data Safety Monitoring Board has approved initiation of the fourth cohort for the ongoing OpRegen® clinical trial.

  • Business Wire4 months ago

    BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018

    BioTime, Inc. , a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2017 financial and operating results on Thursday, March 15, 2018, after the close of the U.S.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes